ONC - מדד נזילות מהירה beigene.com

BeiGene Ltd (ONC) is investing billions into the development of targeted anti-cancer agents, as confirmed by the quick ratio, where the latest parameter stands at 3.15. Demand for therapy remains stable regardless of economic cycles. Driven by the success of Brukinsa and FDA support, BeiGene Ltd (ONC) is rapidly expanding its ecosystem, providing patients with access to safe and innovative treatment methods.

For BeiGene Ltd (ONC), a leader in the development of targeted oncology drugs, the cash ratio reflects the ability to fund global clinical trials without selling off inventories. This metric assesses solvency by comparing cash and accounts receivable against short-term liabilities. Excluding inventory from the calculation ensures protection against liquidity gaps in the event of a sharp shift in demand. Such financial stability allows BeiGene Ltd (ONC) to maintain affordable pricing while expanding its market share.